JP2022547948A - 片頭痛の処置のための併用療法 - Google Patents

片頭痛の処置のための併用療法 Download PDF

Info

Publication number
JP2022547948A
JP2022547948A JP2022515624A JP2022515624A JP2022547948A JP 2022547948 A JP2022547948 A JP 2022547948A JP 2022515624 A JP2022515624 A JP 2022515624A JP 2022515624 A JP2022515624 A JP 2022515624A JP 2022547948 A JP2022547948 A JP 2022547948A
Authority
JP
Japan
Prior art keywords
cgrp
antibody
patient
migraine
igfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547948A5 (cg-RX-API-DMAC10.html
Inventor
リチャード クレイグ
リサ ウォン
カエ プシック
アヤ プシック
マーティン サンダース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2022547948A publication Critical patent/JP2022547948A/ja
Publication of JP2022547948A5 publication Critical patent/JP2022547948A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022515624A 2019-09-09 2020-09-09 片頭痛の処置のための併用療法 Pending JP2022547948A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962897686P 2019-09-09 2019-09-09
US62/897,686 2019-09-09
US201962946122P 2019-12-10 2019-12-10
US62/946,122 2019-12-10
PCT/US2020/070511 WO2021051130A1 (en) 2019-09-09 2020-09-09 Combination therapy for the treatment of migraines

Publications (2)

Publication Number Publication Date
JP2022547948A true JP2022547948A (ja) 2022-11-16
JP2022547948A5 JP2022547948A5 (cg-RX-API-DMAC10.html) 2023-09-27

Family

ID=74866081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515624A Pending JP2022547948A (ja) 2019-09-09 2020-09-09 片頭痛の処置のための併用療法

Country Status (6)

Country Link
US (1) US12324827B2 (cg-RX-API-DMAC10.html)
EP (1) EP4027984A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022547948A (cg-RX-API-DMAC10.html)
AU (1) AU2020346186A1 (cg-RX-API-DMAC10.html)
CA (1) CA3153776A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021051130A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102775899B1 (ko) * 2023-12-19 2025-02-28 한림대학교 산학협력단 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133562A1 (en) * 2022-01-07 2023-07-13 Endosome Therapeutics, Inc. Methods of treating pain
EP4780481A1 (en) * 2023-09-18 2026-07-29 Ohio State Innovation Foundation Treating gliomas with calcitonin gene-related peptide antagonist

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965520A (en) * 1996-07-25 1999-10-12 Research Corporation Technologies Therapeutic treatment of rheumatoid arthritis and polymyalgia rheumatica
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US20190135927A1 (en) * 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101865T3 (es) 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
CA2349290A1 (en) 1998-11-19 2000-06-02 Elan Corporation, Plc Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
WO2002086105A1 (en) 2001-04-20 2002-10-31 Chiron Corporation Delivery of polynucleotide agents to the central nervous sysstem
JP2005534650A (ja) 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US9408405B2 (en) * 2003-10-03 2016-08-09 Veijlen N.V. Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
SI3045182T1 (en) * 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
BRPI0812768A2 (pt) 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
US8197858B2 (en) 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
DK2734634T3 (da) * 2011-07-22 2019-10-21 Univ Chicago Igf-1 til anvendelse til behandling af migræne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965520A (en) * 1996-07-25 1999-10-12 Research Corporation Technologies Therapeutic treatment of rheumatoid arthritis and polymyalgia rheumatica
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US20190135927A1 (en) * 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102775899B1 (ko) * 2023-12-19 2025-02-28 한림대학교 산학협력단 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램

Also Published As

Publication number Publication date
US20210077591A1 (en) 2021-03-18
US12324827B2 (en) 2025-06-10
EP4027984A4 (en) 2023-10-18
AU2020346186A1 (en) 2022-04-07
WO2021051130A1 (en) 2021-03-18
CA3153776A1 (en) 2021-03-18
EP4027984A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
US11542323B2 (en) Agents, uses and methods for the treatment of synucleinopathy
US20210093718A1 (en) Neutralizing anti-tl1a monoclonal antibodies
ES2957214T3 (es) Composiciones y métodos para anticuerpos contra la BMP6
KR20190086471A (ko) 염증 질환의 치료 방법
EP3555127B1 (en) Agents, uses and methods
JP6764318B2 (ja) 幹細胞因子阻害剤
CN110381988A (zh) 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
US12324827B2 (en) Combination therapy for the treatment of migraines
CN112424226A (zh) 用于治疗重度哮喘的抗cd6抗体
HK40127009A (en) Agents, uses and methods for the treatment of synucleinopathy
US20200331978A1 (en) Compositions and Methods for Treating or Preventing Endocrine FGF23-Linked Diseases
HK1254358B (en) Agents, uses and methods for the treatment of synucleinopathy
HK40013648B (en) Agents, uses and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220518

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250417